Gefitinib can penetrate the brain and thus positively affects non-EGFR targets that participate in AD pathology in E4FAD (APOE4-expressing) AD transgenic (Tg) mice (Thomas et al., 2016). This evidence concerns the gene EGFR and Alzheimer disease.